[{"id":"c679c891-db2e-48af-a57b-9b8c26706382","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381797","created_at":"2021-01-18T01:19:39.832Z","updated_at":"2024-07-02T16:37:16.033Z","phase":"Phase 2","brief_title":"Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma","source_id_and_acronym":"NCT00381797","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KDR • EPAS1 • CA9","pipe":" | ","alterations":" VEGFA overexpression • VEGFA expression • CA9 expression","tags":["KDR • EPAS1 • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA overexpression • VEGFA expression • CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • irinotecan"],"overall_status":"Completed","enrollment":" Enrollment 97","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2017-11-28"}]